Claims for Patent: 8,513,292

Summary for Patent: 8,513,292

Title:	Compositions and methods for the treatment of cancer
Abstract:	The present invention relates to pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound or pyrrolidine-2,5-dione compound of the present invention. (Ia) (Ib) (IIa) (IIIb) Where U is independently selected from: (I) or (II) ##STR00001## where U is independently selected from: ##STR00002##
Inventor(s):	Westlund; Neil (Groton, MA), Hill; Jason (Auburndale, MA), Ashwell; Mark A. (Carlisle, MA), Namdev; Nivedita (Westford, MA), Wang; Jianqiang (Acton, MA), Ali; Syed (North Andover, MA)
Assignee:	ArQule, Inc. (Woburn, MA)
Application Number:	12/664,345
Patent Claims:	1. A compound of formula Ia, Ib, IIa, or IIb, or a pharmaceutically acceptable salt thereof: ##STR00050## Where U is independently selected from: ##STR00051## wherein: R1, R2, and R3 are independently selected from the group consisting of H, F, Cl, Br, I, --NR7R8, --(C.sub.1-C.sub.6) substituted alkyl, --(C.sub.3-C.sub.9)cycloalkyl, --(C.sub.3-C.sub.9) substituted cycloalkyl, --O--(C.sub.1-C.sub.6) alkyl, --O--(C.sub.3-C.sub.9) cycloalkyl, and --O--(C.sub.3-C.sub.9) substituted cycloalkyl, aryl, heteroaryl, and heterocyclyl; R4, R7, and R8 are independently selected from the group consisting of H, --(C.sub.1-C.sub.4) alkyl, and --(C.sub.1-C.sub.4) substituted alkyl; R5 is selected from the group consisting of H, --(C.sub.1-C.sub.6) alkyl, and --CH.sub.2R6; R6 is selected from the group consisting of --O--P(.dbd.O)(OH).sub.2, --O--P(.dbd.O)(--OH)(--O--(C.sub.1-C.sub.6) alkyl), --O--P(.dbd.O)(--O--(C.sub.1-C.sub.6 alkyl).sub.2, --O--P(.dbd.O)(--OH) (--O--(CH.sub.2)-phenyl), --O--P(.dbd.O)(--O--(CH.sub.2)-phenyl).sub.2, a carboxylic acid group, an amino carboxylic acid group, and a peptide; R9 is selected from the group consisting of H, --(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6) substituted alkyl, --(C.sub.3-C.sub.9)cycloalkyl, --(C.sub.3-C.sub.9) substituted cycloalkyl, aryl, heteroaryl, and heterocyclyl; Q is selected from the group consisting of aryl, heteroaryl, heterocyclyl, alkyl, substituted aryl, substituted heteroaryl, substituted heterocyclyl, and substituted alkyl; T is --CH.sub.2--, --C(O)--, or a bond; when T is a bond, then Y is a bond, W is bond, X is --CH.sub.2--, and m=1, n=0; V and Z are independently selected from the group consisting of O, S, and H.sub.2; X is --CH.sub.2--; Y and W are independently --CH.sub.2--, or a bond; m is 1 or 2; n is 1 or 2. 2. The compound of claim 1, wherein Q is an indolyl group or an indolyl group substituted with one or more substituents independently selected from the group consisting of: F, Cl, Br, I, --(C.sub.1-C.sub.6)alkyl, --(C.sub.1-C.sub.6)fluoro-substituted alkyl, --(C.sub.3-C.sub.9)cycloalkyl, --(C.sub.3-C.sub.9)fluoro-substituted cycloalkyl, --O--(C.sub.1-C.sub.6)alkyl, --O--(C.sub.1-C.sub.6)fluoro-substituted alkyl, --O--(C.sub.3-C.sub.9)cycloalkyl, and --O--(C.sub.3-C.sub.9)fluoro-substituted cycloalkyl, -aryl, --O-aryl, --O--(C.sub.1-C.sub.4)alkyl-aryl, --O--(C.sub.1-C.sub.4)alkyl-heterocycle, and --S(.dbd.O).sub.2--(C.sub.1-C.sub.6)alkyl. 3. The compound of claim 1, wherein Q is selected from the group consisting of 2-chlorophenyl and 3-methoxyphenyl. 4. The compound of claim 1 wherein both V and Z are O. 5. The compound of claim 1 wherein R5 is H. 6. The compound of claim 1 wherein Y is a bond. 7. The compound of claim 6 wherein m is 2. 8. The compound of claim 7 wherein W is --CH.sub.2--. 9. The compound of claim 8 wherein n is 1. 10. The compound of claim 1 wherein U is ##STR00052## 11. The compound of claim 1 wherein T is --CH.sub.2--. 12. The compound of claim 1 wherein T is --C(O)--. 13. The compound of claim 1 wherein U is ##STR00053## 14. The compound of claim 1 wherein U is ##STR00054## 15. The compound of claim 1, wherein the compound is selected from the group consisting of (.+-.)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-ylmethyl)-4-(1- H-indol-3-yl)-pyrrolidine-2,5-dione, (.+-.)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-carbonyl)-4-(1H- -indol-3-yl)-pyrrolidine-2,5-dione, (.+-.)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-8-yl)-4-(1H-indo- l-3-yl)-pyrrolidine-2,5-dione, (.+-.)-trans-3-(5-bromo-1H-indol-3-yl)-4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij- ]quinolin-8-yl)-pyrrolidine-2,5-dione, (.+-.)-trans-3-(2-Chloro-phenyl)-4-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quino- lin-8-yl)-pyrrolidine-2,5-dione, (.+-.)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-8-yl)-4-(3-metho- xy-phenyl)-pyrrolidine-2,5-dione, and (.+-.)-trans-3-(4,5-dihydro-pyrrolo[3,2,1-hi]indol-1-yl)-4-(1H-indol-3-yl- )-pyrrolidine-2,5-dione. 16. A pharmaceutical composition comprising a compound of formula Ia, Ib, IIa, or IIb as defined in claim 1 or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or excipients. 17. The pharmaceutical composition of claim 16 further comprising a chemotherapeutic agent. 18. The pharmaceutical composition of 17, wherein said chemotherapeutic agent is selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, trastuzumab, imatanib, paclitaxel, cyclophosphamide, lovastatin, minosine, gemcitabine, arabinofuranosyl cytidine, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristin, vinblastin, nocodazole, teniposide, etoposide, gemcitabine, epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin or idarubicin. 19. A method of treating a cell proliferative disorder, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula Ia, Ib, IIa, or IIb as defined in claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, wherein said cell proliferative disorder is lung cancer, colon cancer, breast cancer, pancreatic cancer, prostate cancer, chronic myelogenous leukemia, melanoma, or ovarian cancer. 20. The method of claim 19, wherein said compound of formula Ia, Ib, IIa, or IIb, or a pharmaceutically acceptable salt thereof, is administered in combination with a chemotherapeutic agent. 21. The method of claim 20, wherein said chemotherapeutic agent is selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, trastuzumab, imatanib, paclitaxel, cyclophosphamide, lovastatin, minosine, gemcitabine, arabinofuranosyl cytidine, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristin, vinblastin, nocodazole, teniposide, etoposide, gemcitabine, epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin or idarubicin. 22. The method of claim 19, wherein said treating comprises a reduction in tumor size. 23. The method of claim 19, wherein the cancer is a metastatic cancer. 24. The method of claim 23, wherein said treating comprises inhibition of metastatic cancer cell invasion. 25. The method of claim 19 wherein the cells with said proliferative disorder contains DNA encoding c-Met. 26. The method of claim 25 wherein the cells have a constitutively enhanced c-Met activity.

Details for Patent 8,513,292

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-06-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2027-06-22
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2027-06-22